MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer

American Journal of Translational Research

Volumn 7, Issue 10, 2015, Pages 2115-2126

  Shen, Rong ^a   Wang, Yu ^a   Wang, Cai Xia ^a   Yin, Miao ^b   Liu, Hong Liang ^c   Chen, Jian Peng ^a   Han, Jun Qing ^a   Wang, Wei Bo ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG NORMAL UNIVERSITY   (China)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; miR 155; SOCS6; STAT3; Tamoxifen resistance

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MICRORNA 155; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENICITY; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; UPREGULATION; WESTERN BLOTTING;

EID: 84947770141     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifenresistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogenactivated protein kinase. J Clin Oncol 2005; 23: 2469-2476.
3. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res 2004; 64: 9199-9208.
4. Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG, Fuqua SA. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res 2007; 13: 3235-3243.
5. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
6. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/ neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-361.
7. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005; 23: 1616-1622.
8. Teng G, Papavasiliou FN. Shhh! Silencing by microRNA-155. Philos Trans R Soc Lond B Biol Sci 2009; 364: 631-637.
9. Sandhu SK, Volinia S, Costinean S, Galasso M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G, Garzon R, Croce CM. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model. Proc Nat Acad Sci U S A 2012; 109: 20047-20052.
10. Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C, Ferracin M, Delmas D, Latruffe N, Croce CM. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogen 2010; 31: 1561-1566.
11. Donnem T, Eklo K, Berg T, Sorbye SW, Lonvik K, Al-Saad S, Al-Shibli K, Andersen S, Stenvold H, Bremnes RM, Busund LT. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Trans Med 2011; 9: 6.
12. Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009; 28: 264-284.
13. Calame K. MicroRNA-155 function in B Cells. Immunity 2007; 27: 825-827.
14. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. Regulation of the germinal center response by microRNA-155. Science 2007; 316: 604-608.
15. Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y, Fan D. miR-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells. FEBS Lett 2014; 588: 2055-2062.
16. Lai RH, Hsiao YW, Wang MJ, Lin HY, Wu CW, Chi CW, Li AF, Jou YS, Chen JY. SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett 2010; 288: 75-85.
17. Hwang MN, Min CH, Kim HS, Lee H, Yoon KA, Park SY, Lee ES, Yoon S. The nuclear localization of SOCS6 requires the N-terminal region and negatively regulates Stat3 protein levels. Biochem Biophys Res Commun 2007; 360: 333-338.
18. Zhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci 2013; 20: 79.
19. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Research 2010; 70: 3119-3127.
20. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiology Biomarkers Prev 2012; 21: 1236-1243.
21. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285: 17869-17879.
22. Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P, Fuxe J. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013; 32: 5614-5624.
23. Czyzyk-Krzeska MF, Zhang X. MiR-155 at the heart of oncogenic pathways. Oncogene 2014; 33: 677-678.
24. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster J M, Coppola D, Sellers TA, Djeu JY, Cheng JQ. Upregulation of miRNA-155 promotestumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 2014; 33: 679-689.
25. Lu Z, Ye Y, Jiao D, Qiao J, Cui S, Liu Z. miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol Lett 2012; 4: 1027-1032.
26. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1236-1243.
27. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 is regulated by the transforming growth factor beta/ Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008; 28: 6773-6784.